ProShare Advisors’s Amphastar Pharmaceuticals AMPH Stock Holding History

ProShare Advisors’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-9,083	Closed	-$243K	–	1875
2025 Q4	$243K	Buy	9,083 +457	+5%	+$11.8K	﹤0.01%	1581
2025 Q3	$230K	Sell	8,626 -1,413	-14%	-$36.5K	﹤0.01%	1621
2025 Q2	$230K	Sell	10,039 -1,038	-9%	-$25.8K	﹤0.01%	1632
2025 Q1	$321K	Sell	11,077 -2,775	-20%	-$88.6K	﹤0.01%	1365
2024 Q4	$514K	Buy	13,852 +2,958	+27%	+$135K	﹤0.01%	1256
2024 Q3	$529K	Buy	10,894 +2,054	+23%	+$90.1K	﹤0.01%	1103
2024 Q2	$354K	Sell	8,840 -2,133	-19%	-$88.4K	﹤0.01%	1171
2024 Q1	$482K	Buy	10,973 +708	+7%	+$36.6K	﹤0.01%	1104
2023 Q4	$635K	Buy	10,265 +1,286	+14%	+$67.6K	﹤0.01%	902
2023 Q3	$413K	Sell	8,979 -69	-0.8%	-$3.76K	﹤0.01%	1012
2023 Q2	$520K	Buy	9,048 +161	+2%	+$7.14K	﹤0.01%	928
2023 Q1	$333K	Sell	8,887 -1,136	-11%	-$37.2K	﹤0.01%	1149
2022 Q4	$281K	Buy	10,023 +637	+7%	+$18.5K	﹤0.01%	1277
2022 Q3	$264K	Buy	9,386 +204	+2%	+$6.66K	﹤0.01%	1223
2022 Q2	$319K	Sell	9,182 -3,994	-30%	-$143K	﹤0.01%	1179
2022 Q1	$473K	Sell	13,176 -2,803	-18%	-$79.5K	﹤0.01%	1310
2021 Q4	$372K	Buy	15,979 +20	+0.1%	+$409	﹤0.01%	1652
2021 Q3	$303K	Sell	15,959 -3,199	-17%	-$62.7K	﹤0.01%	1543
2021 Q2	$386K	Buy	19,158 +1,768	+10%	+$33.3K	﹤0.01%	1720
2021 Q1	$319K	Buy	17,390 +1,290	+8%	+$24K	﹤0.01%	1768
2020 Q4	$324K	Buy	16,100 +3,324	+26%	+$64.7K	﹤0.01%	1558
2020 Q3	$240K	Buy	12,776 +7	+0.1%	+$141	﹤0.01%	1317
2020 Q2	$287K	Buy	+12,769	New	+$234K	﹤0.01%	1252
2020 Q1	–	Sell	-15,956	Closed	-$308K	–	1182
2019 Q4	$308K	Sell	15,956 -1,785	-10%	-$34.2K	﹤0.01%	1328
2019 Q3	$352K	Sell	17,741 -733	-4%	-$15.3K	﹤0.01%	1141
2019 Q2	$390K	Sell	18,474 -2,005	-10%	-$41.9K	﹤0.01%	1121
2019 Q1	$418K	Buy	20,479 +136	+0.7%	+$3.05K	﹤0.01%	1094
2018 Q4	$405K	Sell	20,343 -3,746	-16%	-$73.8K	﹤0.01%	1027
2018 Q3	$463K	Sell	24,089 -1,343	-5%	-$23.9K	﹤0.01%	1146
2018 Q2	$388K	Sell	25,432 -1,561	-6%	-$27.3K	﹤0.01%	1239
2018 Q1	$506K	Sell	26,993 -4,239	-14%	-$79.7K	﹤0.01%	1093
2017 Q4	$601K	Buy	31,232 +2,025	+7%	+$37.8K	﹤0.01%	1040
2017 Q3	$522K	Buy	29,207 +1,992	+7%	+$32.8K	﹤0.01%	945
2017 Q2	$486K	Sell	27,215 -2,283	-8%	-$36.2K	﹤0.01%	976
2017 Q1	$428K	Sell	29,498 -7,423	-20%	-$117K	﹤0.01%	1068
2016 Q4	$680K	Buy	36,921 +4,262	+13%	+$82.9K	0.01%	941
2016 Q3	$620K	Sell	32,659 -5,078	-13%	-$92.2K	0.01%	861
2016 Q2	$608K	Buy	37,737 +524	+1%	+$7.39K	0.01%	883
2016 Q1	$447K	Sell	37,213 -3,614	-9%	-$42.6K	0.01%	1047
2015 Q4	$581K	Buy	40,827 +3,215	+9%	+$42.5K	0.01%	974
2015 Q3	$440K	Sell	37,612 -2,133	-5%	-$32K	0.01%	976
2015 Q2	$699K	Buy	39,745 +1,987	+5%	+$31K	0.01%	944
2015 Q1	$565K	Buy	37,758 +6,210	+20%	+$83K	0.01%	1116
2014 Q4	$366K	Buy	+31,548	New	+$344K	﹤0.01%	1373

Other funds holding AMPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

ProShare Advisors's AMPH Position: Q1 2026 in Review

ProShare Advisors sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2026, closing a stake of 9,083 shares — an estimated $243K sold.

ProShare Advisors first reported a position in AMPH in Q4 2014 and held it in 44 quarters. The position peaked at $699K in Q2 2015. 215 funds tracked by Wall St. Rank hold AMPH as of Q1 2026.

ProShare Advisors reported no remaining Amphastar Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
ProShare Advisors sold 9,083 Amphastar Pharmaceuticals shares in Q1 2026, an estimated $243K.
ProShare Advisors first reported a position in Amphastar Pharmaceuticals in Q4 2014 and held it in 44 quarters.
ProShare Advisors's Amphastar Pharmaceuticals position peaked at $699K in Q2 2015.
215 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.